Spinal fluid CRF reduction in Alzheimer's disease

M. Maral Mouradian, John M. Farah, Erich Mohr, Giovanni Fabbrini, Thomas L. O'Donohue, Thomas N. Chase

Research output: Contribution to journalArticlepeer-review

Abstract

Abnormalities in several neurotransmitters, including neuropeptides, have been found in postmortem studies of Alzheimer's disease (AD). Recently, corticotropin-releasing factor (CRF) was found to be diminished in cerebral cortex. In this study spinal fluid CRF-immunoreactivity (CRF-I) was determined in 16 patients with mild to moderate AD and 9 age-matched controls. Mean CRF-I levels were significantly lower in Alzheimer patients compared with controls. Furthermore, a tendency for a CRF-I increment with successive spinal fluid aliquots in control subjects was absent in Alzheimer patients. CRF-I levels failed to correlate with measures of disease severity or various tests of cognitive function. These results suggest that involvement of CRF containing neurons may play a secondary rather than primary role in the pathophysiology of AD.

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalNeuropeptides
Volume8
Issue number4
DOIs
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Clinical Neurology
  • Neuroscience(all)
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Spinal fluid CRF reduction in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this